Neurotransmitters in Prevention and Treatment of Alzheimer’s Disease

Author:

Yang Zhenqi1,Zou Yong1,Wang Lifeng1

Affiliation:

1. Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China

Abstract

Alzheimer’s disease (AD) is the most frequent cause of cognitive impairment in middle-aged and older populations. There is a lack of drugs that demonstrate significant efficacy in AD, so the study of the pathogenesis of AD is of great importance. More efficacious interventions are needed, as reflected by our population’s fast aging. Synaptic plasticity is the capacity of neurons to adjust their connections, and it is strongly tied to learning and memory, cognitive function, and brain injury recovery. Changes in synaptic strength, such as long-term potentiation (LTP) or inhibition (LTD), are thought to represent the biological foundation of the early stages of learning and memory. The results of numerous studies confirm that neurotransmitters and their receptors play an important role in the regulation of synaptic plasticity. However, so far, there is no definite correlation between the function of neurotransmitters in aberrant neural oscillation and AD-related cognitive impairment. We summarized the AD process to understand the impact of neurotransmitters in the progression and pathogenesis of AD, including the current status of neurotransmitter target drugs, and the latest evidence of neurotransmitters’ function and changes in the AD process.

Funder

National Natural Science Foundation of China

Logistics Research Program

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference100 articles.

1. Therapeutics of Neurotransmitters in Alzheimer’s Disease;Kandimalla;J. Alzheimers Dis.,2017

2. Arumugam, Dong-Gyu Jo, Physiology and pharmacology of amyloid precursor protein;Cho;Pharmacol. Ther.,2022

3. The link between C-reactive protein and Alzheimer’s disease among mexican Americans;Johnson;J. Alzheimer’s Dis. Jad,2012

4. A vicious cycle of β amyloid-dependent neuronal hyperactivation;Zott;Science,2019

5. Tau immunotherapies for Alzheimer’s disease;Hoskin;Expert Opin. Investig. Drugs,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3